SIGA TECHNOLOGIES INC SIGA

Healthcare SIC 2834 - Pharmaceutical Preparations NAICS Manufacturing › Chemical Manufacturing › Pharmaceutical and Medicine Manufacturing › Pharmaceutical Preparation Manufacturing derived Nasdaq

SIGA Technologies, Inc. is referred to throughout this report as "SIGA," "the Company," "we" or "us."

We are a commercial-stage pharmaceutical company. The Company sells its lead product, TPOXX® ("oral TPOXX®," also known as "tecovirimat," "Tecovirimat-SIGA," or "TEPOXX (tecovirimat)" in certain international markets), to the U.S. Government and international governments (including government affiliated entities). In certain international markets, the Company may sell TPOXX® through a distributor. Additionally, the Company sells the intravenous formulation of TPOXX® ("IV TPOXX®") to the U.S. Government.

TPOXX® is an antiviral drug for the treatment of human smallpox disease caused by variola virus. On July 13, 2018, the United States Food & Drug Administration ("FDA") approved the oral formulation of TPOXX® for the treatment of smallpox. The Company has been delivering oral TPOXX® to the U.S. Strategic National Stockpile ("Strategic Stockpile") since 2013.

Last close 3.12 2026-10-23
Market cap $224.2M 2026-06-30 share count
52-week range 2.83 - 8.54

Valuation FY2025 figures against the last close

P/S2.4x
P/E9.8x
P/FCF5.2x
EV/EBITDA9.2x
Dividend yield19.2%
Diluted EPS0.32

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $94.6M$138.7M$139.9M$110.8M$133.7M$125.0M$26.7M$477.1M$12.3M$15.0M
Cost of revenue $29.7M$31.3M$17.8M$10.4M$16.6M$14.8M$1.8M$95.3M$0$0
Gross profit $64.9M$107.4M$122.1M$100.3M$117.1M$110.2M$25.0M$381.8M$12.3M$15.0M
R&D $20.0M$12.3M$16.4M$22.5M$9.9M$10.9M$13.3M$13.0M$16.7M$19.7M
SG&A $21.2M$25.1M$22.0M$35.1M$18.0M$14.7M$13.3M$12.9M$12.3M$13.7M
Total operating expenses $70.9M$68.7M$56.3M$68.1M$44.6M$40.5M$29.1M$122.0M$31.1M$46.0M
Operating income $23.7M$70.0M$83.6M$42.7M$89.1M$84.5M-$2.3M$355.1M-$18.8M-$31.0M
Interest expense ———$0$0$3.0M$15.8M$15.5M$14.8M$2.4M
Pre-tax income $30.4M$76.1M$87.8M$44.1M$89.3M$73.5M-$10.2M$411.6M-$38.3M-$39.7M
Income tax $7.1M$16.9M$19.7M$10.2M$19.9M$17.2M$2.9M$10.2M$2.1M$13.9K
Net income $23.3M$59.2M$68.1M$33.9M$69.5M$56.3M-$7.2M$421.8M-$36.2M-$39.7M
EPS, basic 0.330.830.950.460.920.71-0.095.28-0.46-0.69
EPS, diluted 0.320.820.950.460.910.71-0.155.18-0.46-0.69
Shares, diluted (wtd. avg.) 71.9M71.9M71.7M73.5M76.4M79.4M82.2M82.7M78.9M57.2M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $155.0M$155.4M$150.1M$98.8M$103.1M$117.9M$65.2M$100.7M$19.9M$28.7M
Receivables $3.3M$21.2M$21.1M$45.4M$83.7M$3.3M$4.2M$2.0M$1.8M$3.2M
Inventory $49.1M$49.6M$64.2M$39.3M$19.5M$20.3M$9.7M$2.9M$3.0M$26.2M
Total current assets $212.9M$231.0M$239.0M$185.8M$208.8M$143.6M$180.0M$121.3M$37.4M$69.2M
Property, plant and equipment $1.1M$1.3M$1.3M$1.8M$2.4M$2.1M$2.6M$171.3K$138.6K$299.5K
Goodwill $898.3K$898.3K$898.3K$898.3K$898.3K$898.3K$898.3K$898.3K$898.3K$898.3K
Total assets $219.5M$244.3M$254.4M$195.0M$214.7M$149.8M$198.6M$203.4M$144.7M$161.0M
Accounts payable $824.5K$1.3M$1.5M$3.4M$2.0M$1.3M$3.1M$1.7M$1.3M$2.5M
Short-term debt —————$0$80.0M$0——
Total current liabilities $18.0M$25.3M$54.1M$21.5M$30.5M$10.5M$91.7M$11.3M$6.8M$7.1M
Total liabilities $20.6M$28.5M$57.5M$24.9M$40.4M$20.0M$100.8M$100.5M$467.8M$448.4M
Retained earnings -$43.1M-$22.8M-$38.9M-$63.8M-$51.8M-$95.2M-$123.0M-$115.8M$200.0K-$501.1M
Total equity $198.8M$215.8M$196.9M$170.2M$174.3M$129.8M$97.8M$102.9M-$323.1M-$287.4M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $43.5M$48.8M$94.8M$41.6M$11.5M$71.5M-$18.2M$68.9M-$18.4M-$116.8M
Depreciation and amortisation $562.6K$538.4K$538.3K$517.6K$522.4K$529.8K$527.0K$69.6K$132.2K$174.3K
Stock-based compensation $3.7M$3.6M$2.1M$1.8M$1.3M$1.4M$2.1M$2.3M$1.1M$775.5K
Capital expenditure $355.0K$42.5K$21.7K$0$50.6K$15.5K$29.1K$102.3K$100.1K$23.9K
Investing cash flow -$355.0K-$42.5K-$21.7K$0-$50.6K-$15.5K-$29.1K$78.2M-$100.1K$1.2M
Financing cash flow -$43.6M-$43.5M-$43.4M-$46.0M-$26.2M-$114.6M-$1.2M-$3.8M-$585.6K$59.1M
Dividends paid $43.1M$42.7M$32.1M$32.9M$0$0————
Buybacks $0$0$11.1M$13.0M$26.0M$28.5M$0$0$84.0K$0

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-017421.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -200M 0 200M 400M 600M Revenue, FY2016: 15M Gross profit, FY2016: 15M Net income, FY2016: -39.7M Revenue, FY2017: 12.3M Gross profit, FY2017: 12.3M Net income, FY2017: -36.2M Revenue, FY2018: 477.1M Gross profit, FY2018: 381.8M Net income, FY2018: 421.8M Revenue, FY2019: 26.7M Gross profit, FY2019: 25M Net income, FY2019: -7.2M Revenue, FY2020: 125M Gross profit, FY2020: 110.2M Net income, FY2020: 56.3M Revenue, FY2021: 133.7M Gross profit, FY2021: 117.1M Net income, FY2021: 69.5M Revenue, FY2022: 110.8M Gross profit, FY2022: 100.3M Net income, FY2022: 33.9M Revenue, FY2023: 139.9M Gross profit, FY2023: 122.1M Net income, FY2023: 68.1M Revenue, FY2024: 138.7M Gross profit, FY2024: 107.4M Net income, FY2024: 59.2M Revenue, FY2025: 94.6M Gross profit, FY2025: 64.9M Net income, FY2025: 23.3M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $15.0M $12.3M $477.1M $26.7M $125.0M $133.7M $110.8M $139.9M $138.7M $94.6M
Gross profit $15.0M $12.3M $381.8M $25.0M $110.2M $117.1M $100.3M $122.1M $107.4M $64.9M
Net income -$39.7M -$36.2M $421.8M -$7.2M $56.3M $69.5M $33.9M $68.1M $59.2M $23.3M

Recent filings and events

  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Results announced Item 2.02
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Results announced Item 2.02
  • Results announced Item 2.02
  • Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
  • Shareholder vote Item 5.07
  • Results announced Item 2.02

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2834

TickerCompanyMarket capP/ERevenue growth
LLY ELI LILLY & Co $1.20T 55.5x 44.7%
JNJ JOHNSON & JOHNSON $635.76B 23.9x 6.0%
ABBV AbbVie Inc. $504.76B 121.0x 8.6%
MRK Merck & Co., Inc. $358.41B 20.0x 1.3%
ABT ABBOTT LABORATORIES $180.63B 27.9x 5.7%
PFE PFIZER INC $171.16B 22.1x -1.6%
VRTX VERTEX PHARMACEUTICALS INC / MA $132.80B 34.2x 8.9%
BMY BRISTOL MYERS SQUIBB CO $125.59B 17.8x -0.2%